Spots Global Cancer Trial Database for First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Official Title: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)

Study ID: NCT04053283

Conditions

Metastatic Cancer

Epithelial Tumor

Interventions

NG-641

Study Description

Brief Summary: To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.

Detailed Description: To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours. The Phase 1a part of the study is a dose-escalation and dose-optimization phase investigating NG-641 administration by intravenous (IV) infusion in a range of tumour types. The Phase 1b part of the study will investigate the selected optimized multicycle dosing regimen as a monotherapy in up to three cohorts of patients with specific tumour types (Dose Expansion Cohorts A, B and C).